VEGFR2-IN-86 is a dual VEGFR2/CDK2 inhibitor, with an IC50 of 0.06 µM against VEGFR2 and an IC50 of 0.78 µM against CDK2. VEGFR2-IN-86 induces G-phase cell cycle arrest, reduces colony-forming ability and tumor cell migration capacity, and exerts antiproliferative activity in cancer cells. VEGFR2-IN-86 can be used for the research of breast cancer and prostate cancer[1].
Molekulargewicht:
329.35
Formel:
C20H15N3O2
Target-Kategorie:
CDK,VEGFR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
